Tislelizumab with chemoradiation for advanced esophagus cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophagus squamous cell cancer confirmed by biopsy or surgery
- Your cancer is advanced, has come back, or has spread, and cannot be removed with curative surgery
- Your tumor PD-L1 level (CPS) is below 10
- You have not had chemotherapy or other cancer medicines as the main first treatment for advanced/spread disease
- You can do day-to-day activities fairly well (ECOG 0 or 1)
- Your scans show at least one measurable tumor spot on CT or MRI within 28 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes at the time of surgery.
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial tests a combination of two drugs (tislelizumab and all trans retinoic acid) plus standard chemotherapy for people with advanced esophageal squamous cell cancer that cannot be removed by surgery. The goal is to see if this new mix helps control the disease better than current treatments.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.